Opthea Limited in brief
Opthea Limited is a listed company in the Biotechnology industry, based in Australia. Its last known market value was $277 M (January 2024); there is no current figure. Its shares trade under the symbol OPT.AX (ASX).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Opthea Limited
Opthea is Biotechnology company with headquarters is in Australia.
Opthea is committed to improving vision in patients suffering from retinal eye diseases.
They are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in conjunction with existing standard of care anti-VEGF-A therapies.
Opthea Limited timeline
- 1991
- 🔔Initial public offering on Australian Securities Exchange as OPT
Events of Opthea Limited from Wikidata. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Australia: #224 (Jan 2020) · #244 (Jan 2021) · #375 (Jan 2022) · #357 (Dec 2022) · #399 (Jul 2023) · #324 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- —
- Liabilities / assets
- 454.0%
- Revenue growth
- +9.1%
- R&D / revenue
- 146941.7%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2025 | — | — | $-156M | $-163M | — |
| Jun 2024 | $0M | +9.1% | $-192M | $-220M | -183533.3% |
| Jun 2023 | $0M | +22.2% | $-150M | $-143M | -129563.6% |
| Jun 2022 | $0M | +28.6% | $-97M | $-93M | -103133.3% |
| Jun 2021 | $0M | +16.7% | — | $-45M | -64771.4% |
| Jun 2020 | $0M | -45.5% | — | $-11M | -18533.3% |
| Jun 2019 | $0M | — | — | $-15M | -13590.9% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2025 | $-159M | $0M | $-159M | $-0.13 | — |
| Jun 2024 | $-161M | $0M | $-161M | $-0.35 | — |
| Jun 2023 | $-121M | $0M | $-121M | $-0.32 | — |
| Jun 2022 | $-71M | $0M | $-71M | $-0.26 | — |
| Jun 2021 | $-46M | $0M | $-46M | $-0.14 | — |
| Jun 2020 | $-6M | $0M | $-6M | — | — |
| Jun 2019 | $-17M | $0M | $-17M | — | — |
SEC filings
- Nov 20, 20256-KReport of foreign issuer
- Nov 12, 20256-KReport of foreign issuer
- Oct 31, 20256-KReport of foreign issuer
- Oct 30, 20256-KReport of foreign issuer
- Oct 27, 20256-KReport of foreign issuer
- Oct 10, 20256-KReport of foreign issuer
- Oct 6, 20256-KReport of foreign issuer
- Sep 15, 202520-FAnnual report (foreign issuer) · period to Jun 2025
- Sep 15, 20256-KReport of foreign issuer
- Aug 29, 20256-KReport of foreign issuer
- Aug 20, 20256-KReport of foreign issuer
- Aug 19, 20256-KReport of foreign issuer
Official filings of Opthea Limited with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-156 M
- Net income
- $-163 M
For year ending June-2025 · source: SEC filing
Balance sheet
- Total assets
- $57 M
- Total liabilities
- $258 M
- Total equity
- $-201 M
As of June-2025
Mutual funds holding Opthea Limited#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Schwab International Small-Cap Equity ETFCharles Schwab Investment Management, Inc. | 2.28 M | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Esg International Stock ETFThe Vanguard Group, Inc. | 206,684 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis International Equity ETFAmerican Century ETF Trust | 200,476 | $0 M | — | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Opthea Limited scorecard#
Passes 0 of the 7 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.13 vs -0.35Diluted EPS -0.13 in fiscal 2025 against -0.35 the year before (report's currency).
- ✗Net income higher than five years earlier-$163 M-$163 M in fiscal 2025 against -$11 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$163 MNet income -$163 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.2×Current ratio 0.22 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year91.9%Diluted shares up 91.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Opthea Limited: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Jun 30, 2025 | FY 2024to Jun 30, 2024 | FY 2023to Jun 30, 2023 | FY 2022to Jun 30, 2022 | FY 2021to Jun 30, 2021 | FY 2020to Jun 30, 2020 | FY 2019to Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 0.0−80.0%100% | 0.1r0.1+15.7%100% | 0.1r0.1+19.1%100% | 0.1+32.2%100% | 0.1+16.2%100% | 0.1−47.5%100% | 0.1—100% | |
| Research and development | 127−28.1%507328% | 176r176+36.9%141061% | 129r122+58.2%119285% | 81r79+215%89814% | 26+115%37736% | 12−46.2%20426% | 22—19929% | |
| General and administrative | 29+84.3%116304% | 16r16−26.9%12622% | 22r28+41.1%19983% | 15r18+14.0%16862% | 13r13+185%19556% | 4.7+27.6%7963% | 3.7—3277% | |
| Total costs and expenses | 156−18.8%623632% | 192r192+27.7%153683% | 150r150+55.5%139269% | 97—106676% | — | — | — | |
| Operating income | −156—−623048% | −192r−192—−153474% | −150r−150—−138912% | −97—−106457% | — | — | — | |
| Interest and finance income | 5.5+62.9%22128% | 3.4r3.4+5.2%2716% | 3.2r3.2+1270%2988% | 0.2−36.7%260% | 0.4r0.4−22.6%542% | 0.5−11.2%813% | 0.5—481% | |
| Interest expense and finance costs | 0.0+33.3%32.0% | 0.0r0.0−100.0%4.8% | 13+227301%12465% | 0.0+2.4%6.5% | 0.0+12.3%8.4% | 0.0—8.7% | — | |
| Income before tax | −170—−678952% | −230r−230—−183723% | −148r−148—−137451% | −99—−109300% | −50—−73285% | −17—−28499% | −25—−22602% | |
| Income tax | −6.9—−27788% | −9.4r−9.4—−7530% | −5.9r−5.9—−5487% | −6.3—−6946% | −4.9—−7198% | −5.7—−9666% | −10—−9311% | |
| Net income including minority interests | −163—−651164% | −220r−220—−176194% | −143r−143—−131964% | −93—−102354% | −45—−66087% | −11—−18833% | −15—−13291% | |
| Net income attributable to shareholders | −163—−651164% | −220r−220—−176194% | −143r−143—−131964% | −93—−102354% | −45—−66087% | −11—−18833% | −15—−13291% | |
| Earnings per share, basic | -0.13—— | -0.35—— | -0.32—— | -0.26—— | -0.14—— | — | — | |
| Earnings per share, diluted | -0.13—— | -0.35—— | -0.32—— | -0.26—— | -0.14—— | — | — | |
| Shares, weighted average (basic) | 1,225+91.9%— | 638+44.2%— | 443+25.9%— | 352r352+9.7%— | 320+22.9%— | 261+12.0%— | 233—— | |
| Shares, weighted average (diluted) | 1,225+91.9%— | 638+44.2%— | 443+25.9%— | 352r352+9.7%— | 320+22.9%— | 261+12.0%— | 233—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 48−71.9%85.3% | 172r172+93.4%91.4% | 89r89+652%90.4% | 12−23.7%19.7% | 16+648%11.2% | 2.1−86.3%4.2% | 15—— | |
| Receivables | 0.4−70.6%0.7% | 1.4r1.4+124%0.8% | 0.6+147%0.6% | 0.3−54.4%0.4% | 0.6+189%0.4% | 0.2—0.4% | — | |
| Current assets | 57−69.8%100% | 188r188+91.3%99.7% | 98+64.2%99.7% | 60−56.6%99.8% | 138+182%99.8% | 49—99.2% | — | |
| Property, plant and equipment | 0−100%0.0% | 0.0r0.0+45.3%0.0% | 0.0+17.6%0.0% | 0.0+20.7%0.0% | 0.0−9.0%0.0% | 0.0—0.1% | — | |
| Right-of-use (leased) assets | 0−100%0.0% | 0.1r0.1−50.1%0.0% | 0.2—0.2% | — | 0.1−44.0%0.1% | 0.2—0.3% | — | |
| Non-current assets | 0−100%0.0% | 0.6r0.6+135%0.3% | 0.3+84.3%0.3% | 0.1−52.6%0.2% | 0.3−25.7%0.2% | 0.4—0.8% | — | |
| Total assets | 57−69.9%100% | 189r189+91.4%100% | 99+64.3%100% | 60−56.6%100% | 138+180%100% | 49—100% | — | |
| Accounts payable | 9.7−74.4%17.1% | 38r38+113%20.2% | 18+56.3%18.1% | 11+358%19.1% | 2.5−38.3%1.8% | 4.1—8.2% | — | |
| Current liabilities | 258+303%454% | 64r64+242%33.9% | 19+55.6%19.0% | 12+288%20.1% | 3.1−34.7%2.2% | 4.8—9.6% | — | |
| Lease liabilities (non-current) | — | — | 0.10.0%0.1% | 0.1—0.1% | — | 0.1—0.2% | — | |
| Non-current liabilities | 0−100%0.0% | 201r201+134%106% | 86+306441%86.9% | 0.0+65.4%0.0% | 0.0−84.6%0.0% | 0.1—0.2% | — | |
| Total liabilities | 258−2.5%454% | 265r265+153%140% | 104+766%106% | 12+286%20.1% | 3.1−35.8%2.3% | 4.9—9.8% | — | |
| Retained earnings | −742—−1307% | −580r−580—−307% | −359—−364% | −217—−361% | −124—−89.7% | −79—−159% | — | |
| Total equity | −201—−354% | −76r−76—−40.2% | −5.9r−5.9−112%−5.9% | 48r48−64.5%79.9% | 135+204%97.7% | 45+104%90.2% | 22—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 0.0−63.2%28.0% | 0.0r0.0+11.8%15.2% | 0.0r0.0+42.7%15.7% | 0.0−20.6%13.1% | 0.0+0.6%21.9% | 0.0−36.8%25.3% | 0.0—21.0% | |
| Share-based compensation | 6.1+20.5%24512% | 5.1r5.1−12.9%4068% | 5.8r5.8+11.1%5403% | 5.3+34.7%5791% | 3.9+432%5681% | 0.7+6.9%1241% | 0.7—609% | |
| Cash from operating activities | −159—−634576% | −161r−161—−128812% | −121r−121—−111674% | −71—−78664% | −46—−66381% | −5.7—−9633% | −17—−15149% | |
| Capital expenditure | −0.0—−52.0% | −0.0r−0.0—−26.4% | −0.0r−0.0—−20.4% | −0.0—−18.6% | −0.0—−18.5% | −0.0—−4.3% | −0.0—−9.2% | |
| Cash from investing activities | −0.0—−52.0% | −0.0r−0.0—−26.4% | −0.0r−0.0—−20.4% | −0.0−103%−18.6% | 0.7+97.0%957% | 0.3+38.9%564% | 0.2—213% | |
| Shares issued | — | — | 82—75755% | — | 105+220%153728% | 33+263%55793% | 9.1—8062% | |
| Cash from financing activities | 35−85.7%139068% | 244r244+45.7%194983% | 167r167+97387%154894% | 0.2−99.9%189% | 117+253%170429% | 33+266%56162% | 9.1—8062% | |
| Exchange-rate effect on cash | −0.1−123%−552% | 0.6r0.6—481% | −2.1r−2.1—−1942% | −2.4−168%−2626% | 3.5—5095% | −0.3—−481% | −1.2—−1090% | |
| Report | 20-F | 20-F | 20-F | 20-F/A | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
How Opthea Limited compares in Biotechnology
- Revenue growth9.1% · higher than 53% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Opthea Limited🇦🇺 | $277 M | — | — | +9.1% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending June-2025
- Balance sheet:
- As of June-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Opthea Limited? Verify and update this profile — free
Show Opthea Limited's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.